ALX Oncology
ALXO
86 hedge funds and large institutions have $410M invested in ALX Oncology in 2022 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 20 increasing their positions, 32 reducing their positions, and 18 closing their positions.
833% more call options, than puts
Call options by funds: $252K | Put options by funds: $27K
17% more capital invested
Capital invested by funds: $349M → $410M (+$61M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.23% less ownership
Funds ownership: 89.42% → 89.19% (-0.23%)
13% less funds holding
Funds holding: 99 → 86 (-13)
38% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 32
61% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$16.7M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$2.03M |
| 3 |
Morgan Stanley
New York
|
+$1.01M |
| 4 |
BlackRock
New York
|
+$345K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$213K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$6.98M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.34M |
| 3 |
Millennium Management
New York
|
-$1.63M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$1.62M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$1.12M |
ALXO Hedge Fund Activity: Q4 2022 in Review
86 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in ALX Oncology (ALXO) for Q4 2022, worth a combined $410M — up 17% from $349M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of ALXO and 7 opened new positions — a net loss of 11 holders — while 32 trimmed existing stakes and 20 added.
The largest buyer was Fidelity Investments, adding an estimated $16.7M. The largest seller was Logos Global Management, cutting an estimated $6.98M.
- 86 institutional investors held ALX Oncology (ALXO) as of Q4 2022, down from 99 in Q3 2022.
- Funds reported $410M of ALX Oncology stock for Q4 2022, up 17% quarter-over-quarter.
- 7 funds opened new ALX Oncology positions in Q4 2022 and 18 closed out, a net change of -11 holders.
- The largest ALX Oncology buyer in Q4 2022 was Fidelity Investments, an estimated $16.7M added.
- The largest ALX Oncology seller in Q4 2022 was Logos Global Management, an estimated $6.98M sold.
Based on aggregated 13F filings for Q4 2022.